New User:

Forgot your password?

Stock Market & Financial Investment News

News For MKGAY;OPXA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
16:15 EDTOPXAFrigate Ventures reports 9.9% passive stake in Opexa Therapeutics
Subscribe for More Information
April 9, 2015
07:03 EDTOPXAOpexa Therapeutics announces completion of rights offering
Subscribe for More Information
April 7, 2015
08:09 EDTMKGAYPfizer, Merck KGaA finalize agreement to co-promote XALKORI
Merck KGaA (MKGAY) and Pfizer (PFE) announced the finalization of the co-promotion agreement allowing the companies to co-promote Pfizerís anaplastic lymphoma kinase inhibitor XALKORI. Under the agreement, XALKORI will be co-promoted in two waves, the first of which will begin in the second and third quarters of 2015 in the United States, Canada, Japan and five European Union countries: France, Germany, Italy, Spain and the United Kingdom. In the U.S. and Canada, XALKORI will be co-promoted by EMD Serono, the U.S. and Canadian biopharmaceutical businesses of Merck KGaA. The second wave will begin in 2016 and includes China and Turkey. n 2015, Merck KGaA will receive a reimbursement associated with its promotion of XALKORI, followed by an 80% for Pfizer, 20% for Merck KGaA profit sharing on the product starting in 2016. The co-promotion term will last through December 31, 2020 for the U.S., Canada, Japan, France, Germany, Italy, Spain and the U.K. and from January 1, 2016 through December 31, 2021 in China and Turkey. Pfizer will report the sales of XALKORI in countries where it is co-promoted with Merck KGaA.
April 6, 2015
08:02 EDTOPXAOpexa Therapeutics notes that rights offering expires on April 8
Opexa Therapeutics provides a reminder to shareholders that its previously announced rights offering will remain open until 5:00 PM Eastern Time on Wednesday, April 8, unless extended. Rights holders will need to exercise their subscription rights prior to that date and time.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use